Crinetics Pharmaceuticals
CRNX
63 hedge funds and large institutions have $473M invested in Crinetics Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 30 increasing their positions, 8 reducing their positions, and 8 closing their positions.
275% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 8
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
17% more capital invested
Capital invested by funds: $404M → $473M (+$69.6M)
4.82% more ownership
Funds ownership: 73.6% → 78.42% (+4.8%)
2% more funds holding
Funds holding: 62 → 63 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$10.4M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.95M |
| 3 |
Goldman Sachs
New York
|
+$4.13M |
| 4 |
BlackRock
New York
|
+$3.82M |
| 5 |
O
OrbiMed
New York
|
+$3.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$4.55M |
| 2 |
EU
Emory University
Atlanta,
Georgia
|
-$2.21M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.06M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$916K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$429K |
CRNX Hedge Fund Activity: Q2 2019 in Review
63 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q2 2019, worth a combined $473M — up 17% from $404M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new CRNX positions and 8 closed out — a net gain of 3 holders — while 30 added to existing stakes and 8 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $10.4M. The largest seller was Artal Group, exiting entirely with an estimated $4.55M sold.
- 63 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q2 2019, up from 62 in Q1 2019.
- Funds reported $473M of Crinetics Pharmaceuticals stock for Q2 2019, up 17% quarter-over-quarter.
- 11 funds opened new Crinetics Pharmaceuticals positions in Q2 2019 and 8 closed out, a net change of +3 holders.
- The largest Crinetics Pharmaceuticals buyer in Q2 2019 was Eventide Asset Management, an estimated $10.4M added.
- The largest Crinetics Pharmaceuticals seller in Q2 2019 was Artal Group, an estimated $4.55M sold.
Based on aggregated 13F filings for Q2 2019.